Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Laura K. Schmalbrock, Krischan Braitsch, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Kathrin Rieger, Katharina S. Goetze

Blood (2021) 138 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2021-150943

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Blood (2021) 138 (Supplement 1): 692.

https://doi.org/10.1182/blood-2021-147256

Published: 2021

Journal Articles

Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²

Marius-Konstantin Klever, Eric Sträng, PhD, Julius Jungnitsch, Uirá Souto Melo, Sara Hetzel, Anna Dolnik, Robert Schöpflin, Jens F. Schrezenmeier, Olga Blau, Jörg Westermann, Konstanze Döhner, Hubert Schrezenmeier, Malte Spielmann, Alexander Meissner, PhD, Stefan Mundlos, Lars Bullinger, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-133787

Published: 2020

Journal Articles

COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen

Jana Ihlow, MD, Ann-Christin von-Bruenneck, MD, Edward Georg Michaelis, MD, Selina Greuel, MD, Verena Heynol, Annika Lehmann, Dr., Helena Radbruch, MD, Jenny Meinhardt, MD, Victor Max Corman, MD, Florian Miller, MD, Hermann Herbst, MDFRCPath, Jörg Westermann, Lars Bullinger, MD, David Horst, MD, Sefer Elezkurtaj, MD

Blood (2020) 136 (Supplement 1): 46.

https://doi.org/10.1182/blood-2020-136199

Published: 2020

Journal Articles

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134718

Published: 2020

Journal Articles

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Blood (2020) 136 (13): 1507–1519.

https://doi.org/10.1182/blood.2019003654

Published: 2020

Includes: Supplemental data

Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Blood (2019) 134 (Supplement_1): 2740.

https://doi.org/10.1182/blood-2019-125584

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Jana Ihlow, MD, Sophia Gross, Leonie Busack, Alma Herneth, Igor-Wolfgang Blau, MD PhD, Ioannis Anagnostopoulos, MD, Michaela Schwarz, MD, Anne Floercken, MD, Lars Bullinger, MD, Jörg Westermann, MD

Blood (2019) 134 (Supplement_1): 1324.

https://doi.org/10.1182/blood-2019-127174

Published: 2019

Journal Articles

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Blood (2019) 134 (19): 1608–1618.

https://doi.org/10.1182/blood.2019001425

Published: 2019

Includes: Supplemental data

Journal Articles

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Blood (2019) 133 (8): 840–851.

https://doi.org/10.1182/blood-2018-08-869453

Published: 2019

Includes: Supplemental data

Journal Articles

Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification

Blood (2018) 132 (Supplement 1): 994.

https://doi.org/10.1182/blood-2018-99-114671

Published: 2018

Journal Articles

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Martin Schönlein, J. Henry M. Däbritz, Dorothy Ngo-Yin Fan, Jana Ihlow, Rolf Schwarzer, Binje Vick, Karsten Spiekermann, Thomas Burmeister, Jörg Westermann, Irmela Jeremias, Clemens A. Schmitt

Blood (2017) 130 (Supplement 1): 1393.

https://doi.org/10.1182/blood.V130.Suppl_1.1393.1393

Published: 2017

Journal Articles

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Richard F. Schlenk, MD, Walter Fiedler, MD, Helmut R. Salih, MD, Gerald Wulf, MD, Felicitas Thol, MD, Andrea Kündgen, MD, Thomas Kindler, MD, Hans-Juergen Salwender, MD, Michael Lübbert, MD, Peter Brossart, MD, Jörg Westermann, MD Prof, Doris Kraemer, MD, Katharina Goetze, MD, Heinz-August Horst, MD PhD, Jürgen Krauter, MD, Michael Girschikofsky, MD, Mark Ringhoffer, MD, Thomas Südhoff, MD, Gerhard Held, MD, Hartmut H. Kirchner, MD, Wolff Schmiegel, MD, Richard Greil, MD, Martin Griesshammer, MD, Elisabeth Lange, MD, Uwe Martens, MD, Bernd Hertenstein, MD, Maike de Wit, Elisabeth Koller, MD, Andreas L. Petzer, MD, Tanja Hesse, MD, Volker Runde, MD, Peter Reimer, MD, Beate S. Schultheis, MD, Heinz Kirchen, MD, Frank Griesinger, MD, Holger Hebart, MD, Gerhard Heil, Stephan Kremers, David Nachbaur, MD, Nadezda Basara, MD, Carsten Schwänen, Daniel Schöndube, MD, Jochen Greiner, Anja Münnich, Daniela Weber, Verena I. Gaidzik, MD, Maria-Veronica Teleanu, MD, Peter Paschka, MD, Frauke Theis, Axel Benner, Michael Heuser, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Hartmut Döhner, MD

Blood (2016) 128 (22): 449.

https://doi.org/10.1182/blood.V128.22.449.449

Published: 2016

Journal Articles

Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Blood (2014) 124 (21): 1254.

https://doi.org/10.1182/blood.V124.21.1254.1254

Published: 2014

Journal Articles

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Anne Flörcken, MD, Schneider Tanja, MD, Anju Singh, MD, Seval Türkmen, MD, Burmeister Thomas, MD PhD, Joannis Anagnostopoulos, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Jörg Westermann, MD PhD

Blood (2014) 124 (21): 1006.

https://doi.org/10.1182/blood.V124.21.1006.1006

Published: 2014

Journal Articles

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT

Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Maike Oey, Andrea Stroux, Philipp Hemmati, Jörg Westermann, Olga Blau, Friedrich Wittenbecher, Kamran Movassaghi, Martin Szyska, Sybill Thomas, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na

Blood (2014) 124 (6): 963–972.

https://doi.org/10.1182/blood-2013-11-539031

Published: 2014

Includes: Supplemental data

Journal Articles

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Blood (2013) 122 (21): 3878.

https://doi.org/10.1182/blood.V122.21.3878.3878

Published: 2013

Journal Articles

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Christoph Ochs, Philipp Hemmati, MD, Giang Lam Vuong, MD, Kathrin Rieger, Olga Blau, Jörg Westermann, MD, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na

Blood (2013) 122 (21): 4605.

https://doi.org/10.1182/blood.V122.21.4605.4605

Published: 2013

NARROW

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²

COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only